We need a new national approach to control hepatitis C: It is becoming too late

Hepatitis Monthly

Volumn 8, Issue 3, 2008, Pages 165-169

  Alavian, Seyed Moayed ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

DISEASE SURVEILLANCE; EDITORIAL; HAND WASHING; HARM REDUCTION; HEALTH CARE PLANNING; HEALTH EDUCATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION RISK; INFORMATION DISSEMINATION; INTRAVENOUS DRUG ABUSE; MEDICAL INSTRUMENTATION; PATIENT COMPLIANCE; PERSONAL HYGIENE; PREVALENCE; PRISON; PUBLIC HEALTH SERVICE; UNSAFE SEX; VIRUS TRANSMISSION;

EID: 56149109296     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Editorial

References (48)

1. Brown RS, Jr., Gaglio PJ. Scope of worldwide hepatitis C problem. Liver Transpl 2003; 9: S10-3.
2. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iranian Med 2005; 8: 84-90.
3. Alavian S, M, Fallahian F, Bagheri-Lankarani K. The Changing Epidemiology of Viral Hepatitis B in Iran. J Gastrointestin Liver Dis 2007; 16: 403-6.
4. Hwang SJ, Lee SD, Lu RH, Chu CW, Wu JC, Lai ST, et al. Hepatitis C viral genotype influences the clinical outcome of patients with acute posttransfusion hepatitis C. J Med Virol 2001; 65: 505-9.
5. Donahue JG, Munoz A, Ness PM, Brown DE, Jr., Yawn DH, McAllister HA, Jr., et al. The declining risk of posttransfusion hepatitis C virus infection. N Engl J Med 1992; 327: 369-73.
6. De Carli G, Puro V, Ippolito G. Risk of hepatitis C virus transmission following percutaneous exposure in healthcare workers. Infection 2003; 31: 22-7.
7. Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002; 155: 645-53.
8. Zhou F, Ma ZE, Hu W, Feng ZL, Chen KL, Qin GM, et al. Study on the relationship between hepatitis C virus infection and sharing injection equipment, sexual behavior among injecting drug users (in Chinese). Zhonghua Liu Xing Bing Xue Za Zhi 2004; 25: 329-32.
9. Vidal-Trecan GM, Varescon-Pousson I, Gagniere B, Tcherny- Lessenot S, Madariaga E, Boissonnas A. Association between first injection risk behaviors and hepatitis C seropositivity among injecting drug users. Ann Med Interne 2002; 153: 219-25.
10. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007; 18: 352-8.
11. Stark K, Bienzle U, Vonk R, Guggenmoos-Holzmann I. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. Int J Epidemiol 1997; 26: 1359-66.
12. Alavian SM, Gholami B, Masarrat S. Hepatitis C risk factors in Iranian volunteer blood donors: A case-control study. J Gastroenterol Hepatol 2002; 17: 1092-7.
13. Alavian SM, Fallahian F. Comparison of Seroepidemiology and Transmission Modes of Viral Hepatitis C in Iran and Pakistan. Hep Mon 2008; 8: 51-9.
14. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86: 655-61.
15. Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy 2007; 18: 359-63.
16. Zali MR, Aghazadeh R, Nowroozi A. Anti-HCV antibody among Iranian IV drug users: is it a serious problem? Arch Iran Med 2001; 4: 115-9.
17. Alizadeh AHM, Alavian SM, Jafari K, Yazdi N. Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan-Iran. World J Gastroenterol 2005; 11: 4085-9.
18. Taylor A, Goldberg D, Frischer M, Emslie J, Green S, McKeganey N. Transmission of HIV in prison. Evidence of risk. BMJ 1993; 307: 623.
19. Muller R, Stark A, Guggenmoos-Holzmann I, Wirth D, Bienzle U. Imprisonment: a risk factor for HIV infection counteracting education and prevention programmes for intravenous drug users. AIDS 1995; 9: 183-90.
20. Carvell ALM, Hart GJ. Risk behaviours for HIV infection among drug users in prison. Br Med J 1990; 300: 1383-85.
21. Covell RG, Frischer M, Taylor A. Prison experience of injecting drug users in Glasgow. Drug Alcohol Depend 1993; 32: 9-14.
22. Stark K, Muller R, Bienzle U, Guggenmoos-Holzmann I. Methadone maintenance treatment and HIV risk-taking behaviour among injecting drug users in Berlin. J Epidemiol Community Health 1996; 50: 534-7.
23. Crofts N, Nigro L, Oman K, Stevenson E, Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction 1997; 92: 999-1005.
24. Samuel MC, Doherty PM, Bulterys M, Jenison SA. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect 2001; 127: 475-84.
25. Hellard ME, Hocking JS, Crofts N. The prevalence and the risk behaviours associated with the transmission of hepatitis C virus in Australian correctional facilities. Epidemiol Infect 2004; 132: 409-15.
26. Hagan H, Des Jarlais DC. HIV and HCV infection among injecting drug users. Mt Sinai J Med 2000; 67: 423-8.
27. Hagan H, Thiede H, Des Jarlais DC. HIV/hepatitis C virus coinfection in drug users: Risk behaviors and prevention. AIDS 2005; 19: S199-207.
28. Rezza G, Sagliocca L, Zaccarelli M, Nespoli M, Siconolfi M, Baldassarre C. Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence. Scand J Infect Dis 1996; 28: 27-9.
29. Thiede H, Hagan H, Murrill CS. Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health 2000; 77: 331-45.
30. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91: 42-6.
31. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002; 186: 1558-64.
32. Judd A, Hickman M, Jones S, McDonald T, Parry JV, Stimson GV, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ 2005; 330: 24-5.
33. Judd A, Hutchinson S, Wadd S, Hickman M, Taylor A, Jones S, et al. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. J Viral Hepat 2005; 12: 655-62.
34. Maher L, Li J, Jalaludin B, Chant KG, Kaldor JM. High hepatitis C incidence in new injecting drug users: a policy failure? Aust N Z J Public Health 2007; 31: 30-5.
35. Hagan H, Des Jarlais DC, Stern R, Lelutiu-Weinberger C, Scheinmann R, Strauss S, et al. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy 2007; 18: 341-51.
36. Mateu-Gelabert P, Treloar C, Calatayud VA, Sandoval M, Zurian JC, Maher L, et al. How can hepatitis C be prevented in the long term? Int J Drug Policy 2007; 18: 338-40.
37. Madden A, Cavalieri W. Hepatitis C prevention and true harm reduction. Int J Drug Policy 2007; 18: 335-7.
38. Paterson BL, Backmund M, Hirsch G, Yim C. The depiction of stigmatization in research about hepatitis C. Int J Drug Policy 2007; 18: 364-73.
39. Crofts N, Caruana S, Bowden S, Kerger M. Minimising harm from hepatitis C virus needs better strategies. BMJ 2000; 321: 899.
40. Crofts N, Jolley D, Kaldor J, van Beek I, Wodak A. Epidemiology of hepatitis C virus infection among injecting drug users in Australia. J Epidemiol Community Health 1997; 51: 692-7.
41. van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ 1998; 317: 433-7.
42. Coutinho RA. HIV and hepatitis C among injecting drug users- Success in preventing HIV has not been mirrored for hepatitis C. BMJ 1998; 317: 424-5.
43. Hopwood M, Treloar C. The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection. Int J Drug Policy 2007; 18: 374-80.
44. Avants SK, Margolin A, Warburton LA, Hawkins KA, Shi J. Predictors of nonadherence to HIV-related medication regimens during methadone stabilization. Am J Addict 2001; 10: 69-78.
45. Scheft H, Fontenette DC. Psychiatric barriers to readiness for treatment for hepatitis C Virus (HCV) infection among injection drug users: clinical experience of an addiction psychiatrist in the HIV-HCV coinfection clinic of a public health hospital. Clin Infect Dis 2005; 40: S292-6.
46. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 2005; 40: S336-8.
47. Jowett SL, Agarwal K, Smith BC, Craig W, Hewett M, Bassendine DR, et al. Managing chronic hepatitis C acquired through intravenous drug use. QJM 2001; 94: 153-8.
48. Robaeys G, Van Vlierberghe H, Mathei C, Van Ranst M, Bruckers L, Buntinx F. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol 2006; 18: 159-66.